皇冠开户
热门标签

皇冠球网:Sanofi ends cancer drug trials

时间:1个月前   阅读:1

皇冠球网www.hg108.vip)是皇冠体育官网线上直营平台。皇冠球网面向亚太地区招募代理,开放皇冠球网代理申请、皇冠球网代理会员开户等业务。皇冠球网可下载皇冠球网APP,皇冠球网APP包括皇冠体育最新代理登录线路、皇冠体育最新会员登录线路。

The decision to stop all studies with amcenestrant follows an analysis of late-stage trial data evaluating the drug in patients with a type of breast cancer, the company said in a statement yesterday.

PARIS: Sanofi is ending development of a key cancer medicine in a blow to the French drugmaker’s pipeline of experimental therapies.

The decision to stop all studies with amcenestrant follows an analysis of late-stage trial data evaluating the drug in patients with a type of breast cancer, the company said in a statement yesterday.

The move leaves Sanofi even more dependent for growth on blockbuster Dupixent, an antibody treatment for ailments ranging from asthma to severe eczema.

The company’s slate of experimental medicines has faced other setbacks, including safety concerns regarding multiple sclerosis treatment tolebrutinib.

,

皇冠开户平台www.hg9988.vip)是皇冠官方开户平台,开放皇冠信用网代理申请、信用网会员开户,线上投注的官方平台。

,

Sanofi has included both amcenestrant and tolebrutinib as among six products in its pipeline that it prioritised as “potentially transformative” treatments.

Some investors are questioning the company’s growth trajectory after both of those medicines encountered problems.

UBS analysts last week downgraded Sanofi, saying there are few major catalysts coming soon to drive more excitement to the stock. — Bloomberg


转载说明:本文转载自Sunbet。

上一篇:Usdt第三方支付(www.trc20.vip):Trading ideas: Carlsberg, Pharmaniaga, Sentral REIT, AirAsia X, Inari Amertron, Hong Leong Industries, TCS, Advancecon, Tenaga, UEM Sunrise and Sapura Energy

下一篇:Allbet代理(www.aLLbet8.vip):Smaller net loss for Pos Malaysia in 2Q

网友评论